RUA Life Sciences (FRA:AOHA) Total Equity: €8.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AOHA RUA Life Sciences PLC FRA:AOHA
48 GF Score
Price €0.24
GF Value €0.14
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is RUA Life Sciences Total Equity?

RUA Life Sciences FRA:AOHA +5.22% 48 Total Equity is €8.12 Mil as of Mar. 2026. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review.

RUA Life Sciences's total equity for the quarter that ended in Mar. 2026 was €8.12 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

RUA Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for RUA Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RUA Life Sciences Total Equity Chart

RUA Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 9.91 7.88 5.31 8.40

RUA Life Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.33 8.40 9.52 8.83 8.12
FRA:AOHA
48GF Score
RUA Life Sciences PLC FRA:AOHA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RUA Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

RUA Life Sciences's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=9.55-1.154
=8.40

RUA Life Sciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=9.916-1.799
=8.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €8.12 Mil mean?
RUA Life Sciences (FRA:AOHA) has a Total Equity of €8.12 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for RUA Life Sciences and its competitors.
Is RUA Life Sciences' Total Equity too high?
RUA Life Sciences' current Total Equity is €8.12 Mil. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Total Equity compare to ABT and SYK?
RUA Life Sciences' Total Equity of €8.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for RUA Life Sciences and its competitors. RUA Life Sciences's current Total Equity is €8.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current Total Equity is €8.12 Mil. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Total Equity is €8.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14. GuruFocus considers RUA Life Sciences to be Significantly Overvalued.

Key valuation signals for FRA:AOHA:

  • Total Equity: €8.12 Mil
  • GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges RUA:UK
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score

Get the complete analysis for FRA:AOHA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.14
GF Value